Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA) and Viridian Therapeutics (VRDN)

Tipranks - Tipranks - Thu Jan 29, 6:56AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HCA Healthcare (HCA – Research Report) and Viridian Therapeutics (VRDN – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

HCA Healthcare (HCA)

Truist Financial analyst David S Macdonald reiterated a Buy rating on HCA Healthcare today and set a price target of $546.00. The company’s shares closed last Tuesday at $505.84.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 11.8% and a 59.5% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, Concentra Group Holdings Parent, Inc., and Ardent Health Partners, Inc. ;'>

HCA Healthcare has an analyst consensus of Moderate Buy, with a price target consensus of $518.14, representing a 2.6% upside. In a report released yesterday, TipRanks – Google also upgraded the stock to Buy with a $541.00 price target.

See the top stocks recommended by analysts >>

Viridian Therapeutics (VRDN)

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Viridian Therapeutics on January 26 and set a price target of $46.00. The company’s shares closed last Tuesday at $33.54.

According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of 31.8% and a 54.3% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., MoonLake Immunotherapeutics, and Amylyx Pharmaceuticals Inc. ;'>

Viridian Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $44.50, representing a 36.3% upside. In a report issued on January 12, Truist Financial also maintained a Buy rating on the stock.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).